Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swedish Mega-Study scans 1,400 for clues to heart, lung, and liver disease

NCT ID NCT07476703

Knowledge-focused Sponsor: Danderyd Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is re-examining 1,400 adults in Stockholm to find early signs and risk factors for heart, lung, and liver diseases. Participants will get advanced scans, blood tests, and questionnaires. The goal is to better understand how these diseases develop and how to predict them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve early detection and risk prediction for heart, lung, and liver diseases, potentially guiding future prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.

Ages

56 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects already included in the main / general SCAPIS reexamination study in Stockholm. Exclusion Criteria: Inability to provide consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic aneurysm Aortic Valve Disease aortic valve disorder chronic obstructive pulmonary disease congenital mitral valve insufficiency and/or stenosis COPD, severe early onset coronary artery disorder Dyslipidemias fatty liver disease heart failure Inflammation lung disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aortic valve diseases Arterial stiffness, blood pressure Coronary artery disease Heart failure Inflammation biomarkers Lipid profile Masld (metabolic dysfunction-associated steatotic liver disease) Metabolic associated-dysfunction steatohepatitis (MASH) Mitral valve stenosis and/or insufficiency Oral microbiota Pulmonary disease, chronic obstructive (COPD) Steatohepatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Research Lab, Dept Cardiology, Danderyd University Hospital

    RECRUITING

    Stockholm, 18288, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.